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CASE 12 
 
Policy Window – When Lyme is in the Limelight 
 
 
Shahzadi Zain, BSc, MBBS, MPH (MPH Class of 2018) 
Michel Deilgat, MD (Medical Advisor, Centre for Food-borne, Environmental and Zoonotic 
Infectious Diseases, Public Health Agency of Canada) 
Amardeep Thind, MD, PhD (Professor, Western University) 
 
It was a bright sunny morning, which was recently an unusual sight for Ottawa, Ontario. Melissa 
Doug, a senior policy analyst at the Centre for Food-Borne, Environmental and Zoonotic 
Infectious Diseases (CFEZID), was on duty to prepare Question Period (QP) notes. The 
CFEZID, which is part of the Infectious Disease Prevention and Control Branch at the Public 
Health Agency of Canada (PHAC), was where Melissa started as a policy analyst almost seven 
years ago. After waking up at 7:30 in the morning, she reached for her phone and was not 
surprised to see a request to prepare a QP note for the Minister of Health. The QP note was to 
contain an update on the status of the activities being undertaken for the Action Plan on Lyme 
Disease (PHAC, 2017). The request was triggered by the recent media attention on the 
alarming rise of Lyme disease cases in Nova Scotia. Melissa was aiming to have the Director’s 
approval by 8:30 a.m. so the QP note with information about current statistics on Lyme disease 
cases in Canada could be forwarded to the Minster of Health for the upcoming roundtable 
discussion.  
 
BACKGROUND: LYME DISEASE IN CANADA 
Lyme disease is an emerging, vector-borne infectious disease in Canada and is caused by the 
bacterium Borrelia burgdorferi. This bacterium is transmitted to people through the bite of an 
infected tick. There are approximately 40 species of ticks in Canada (CFEZID, 2017), but only 
some of them transmit the pathogens causing human illness. B. burgdorferi is exclusively 
transmitted by blacklegged ticks (also called deer ticks) and western blacklegged ticks (CFEZID, 
2017). Lyme disease is the most common tick-borne illness in Canada, and the risk of 
contracting Lyme disease exists in southern parts of British Columbia and Manitoba, Southern 
and Eastern Ontario, Southern Quebec, New Brunswick, and some areas in Nova Scotia 
(Ogden, Koffi, Pelcat, & Lindsay, 2014). In 2018, the PHAC released a map of Lyme disease 
risk areas in Canada (Exhibit 1). The geographical distribution of Lyme disease risk is 
expanding because of warming weather, and the consequent geographical invasion of alternate 
host animals such as migratory birds and dusky-footed wood rats carrying ticks (Ogden et al., 
2014).  
 
People engaging in outdoor activities in affected forested areas for either occupational or leisure 
activities such as camping, hiking, gardening, golfing, dog walking, hunting, fishing, or simply 
sitting outdoors or near compost piles, are at a higher risk of acquiring the disease from tick 
bites (CFEZID, 2017). 
 
Lyme disease became nationally notifiable in 2009 to allow the authorities to monitor and control 
the rising incidence of the disease. About 144 cases were reported that year and were 
estimated to have been underreported because of insufficient awareness about the disease 
among frontline clinicians. Since then, the number of newly diagnosed cases has been steadily 
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increasing and almost 1,000 Canadians were diagnosed with Lyme disease in 2016 (CFEZID, 
2017). The rise in the number of Lyme disease cases reported may be attributed to the 
implementation of a new surveillance system, as well as the advancement in disease 
knowledge and diagnostic procedures. However, there is still some likelihood that cases are 
underreported because of gaps in both the surveillance system and the reporting system 
(CFEZID, 2017). Nova Scotia reported the highest incidence of Lyme disease in Canada in 
2016 at 34.4 per 100,000 people, which is 12.7 times the national average (PHAC, 2018b). 
 
EVOLUTION OF THE FEDERAL RESPONSE ON LYME DISEASE—THE CHALLENGE 
Lyme disease poses a rapidly evolving challenge for public health professionals and frontline 
clinicians. Inconsistencies in clinical practices, such as variable diagnostic approaches (clinical 
diagnosis versus laboratory diagnosis), variable treatment protocols (post-exposure antibiotic 
prophylaxis versus symptomatic treatment), and controversies surrounding the reliability of 
laboratory testing technology necessitate that the best practice guidelines for Lyme disease be 
developed at the national level (CFEZID, 2017). Tick bites may go unnoticed because of the 
extremely small size of the ticks and the painless nature of the bite. This may result in a delayed 
or inaccurate diagnosis and potential for illness to become severe, which makes primary 
prevention even more important. Capturing the exact number of people with Lyme disease by 
compiling data collected from provincial and territorial public health authorities is another 
challenging aspect of Lyme disease surveillance because of the discrepancies in data on travel-
acquired cases and the dynamic and varying provincial disease reporting systems (PHAC, 
2018b). 
 
These challenges, along with the emerging nature of Lyme disease and its link to climate 
change, led to a unified public health response to Lyme disease in the form of a federal 
framework. The Federal Framework on Lyme Disease Act was assented in 2014 and mandated 
the Minister of Health to organize a conference to develop the federal response on tackling 
Lyme disease (Federal Framework on Lyme Disease Act, 2014). Six months later, the Canadian 
Institutes of Health Research, in collaboration with the PHAC, organized a Best Brains 
Exchange1 (Canadian Institutes of Health Research, 2016). This meeting provided an 
opportunity to exchange and brainstorm ideas for effective and evidence-based diagnostic and 
treatment protocols for Lyme disease. Participants included national and international experts, 
including policy-makers, researchers, and other key stakeholders. In May 2016, the PHAC, on 
behalf of the Minister of Health, organized a national conference to inform and guide policy 
direction on Lyme disease (PHAC, 2017). Representatives from health care provider 
associations, all levels of government, academia, patients, and advocacy groups participated in 
the conference and provided feedback on the draft federal framework on Lyme disease.  
 
The final version of the framework was published in May 2017. It outlines three key pillars for 
the federal public health response in the areas of adequate prevention, early diagnosis, and 
timely treatment of Lyme disease. The three pillars—surveillance, education and awareness, 
and guidelines and best practices—lay the foundation for the PHAC Action Plan on Lyme  
Disease (PHAC, 2017).  
 
                                                
1 Best Brains Exchanges are one-day, in-camera gatherings for policy makers, researchers, and field specialists with 
expertise on a topic that has been recognized as a high priority by provincial/territorial ministries of health and the 
Health Portfolio (the Canadian Food Inspection Agency, the Canadian Institutes of Health Research, Health Canada, 
the Patented Medicine Prices Review Board, and the PHAC) in order to support and facilitate the exchange and use 
of information for mutual learning and benefit (Canadian Institutes of Health Research, 2018). 
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FEDERAL FRAMEWORK ON LYME DISEASE—ENGAGEMENT STRATEGY 
A comprehensive approach to Lyme disease prevention and control requires multidisciplinary 
collaboration with relevant stakeholders and partners. Stakeholders hold a diverse range of 
concerns and perspectives regarding the prevention, diagnosis, treatment, and control of Lyme 
disease. They are also concerned with the usefulness, consistency, and comprehensiveness of 
the information available to public health and primary health care practitioners, as well as the 
general population, on the topic of Lyme disease. 
 
Melissa is a part of the Lyme Disease Working Group at the PHAC. Melissa and her team have 
prepared an engagement strategy to facilitate the implementation of the Action Plan on Lyme 
Disease (PHAC, 2018c). The Lyme Disease Working Group consists of policy analysts, a 
technical lead on epidemiology, and a Health Professional Task Force, and it is divided into a 
policy arm and a health professional arm. The policy analysts synthesize evidence into policy 
and keep the rest of the department informed on all policy aspects related to Lyme disease. The 
technical lead supports the team by tracking and keeping the group updated on surveillance 
activities. The health care professional task force consists of medical advisors and nurse 
consultants who positively influence evidence-based decision making, provide insight into best 
practices and guidelines, and synthesize educational and health promotional material for 
primary care practitioners. The policy analysts and the health professional groups hold biweekly 
meetings to collaborate as needed, to debrief the department about Action Plan on Lyme Dise-
ase activities, and to ensure that their work is progressing and is mutually inclusive. 
 
The engagement strategy also aims to encourage information sharing, knowledge translation, 
and partnership building to establish a mutually beneficial relationship between the Government 
of Canada and various Lyme disease stakeholders (PHAC, 2018c). Building coalitions and 
engaging stakeholders are central to achieving effective outcomes in terms of the three pillars of 
the Action Plan. Working collaboratively with partners and stakeholders to improve educational 
and awareness tools will enrich existing prevention and control efforts. The engagement 
activities also enable stakeholders to share their expertise and personal experience to devise 
innovative methods for surveillance and control (PHAC, 2018c). Feedback received from 
various stakeholders about knowledge available to public health practitioners, physicians, and 
the public about Lyme disease helps to identify the gaps in public health response and research 
(PHAC, 2018c). 
 
Stakeholder engagement is crucial at each step of the Action Plan, from planning to 
implementation and then to evaluation. A multipronged approach is required to address the 
needs and interests of different participants (Mitton, Smith, Peacock, Evoy, & Abelson, 2009). 
For example, requests for feedback on the documents can be combined with technical 
workshops depending on the expertise, experience, or interest of the audience. Audience 
segmentation can guide the right approach and the appropriate platform for developing and 
exercising engagement activities. Keeping in mind their level of technical expertise and busy 
schedules, health care professionals may benefit more from technical webinars and workshops. 
Conversely, online consultation tools might benefit individuals with a general interest and 
investment in Lyme disease. Potential platforms useful for engagement activities include email 
notifications, government websites, social media channels, and bilateral meetings. 
 
STAKEHOLDERS 
The engagement strategy aims to identify and attract a broad range of interested partners who 
have diverse areas of expertise, knowledge, and viewpoints. Potential stakeholders include 
public health practitioners at all levels of government (municipal, provincial/territorial, and 
federal), academia, researchers, health care professionals, professional associations, 
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nongovernment organizations, advocacy groups, patients and their caregivers, at-risk 
populations, the media, and the general public (PHAC, 2018c). 
 
Identification and acknowledgement of various influential groups’ perspectives is followed by 
interacting and managing the stakeholders in an appropriate way (Brugha & Varvasovszky, 
2000). Analyzing various characteristics of the stakeholder groups such as level of interest and 
commitment, level of influence, public perception, supporting or opposing positions, priorities, 
sources of funding, and conflicts of interest is one method of managing the wide variety of 
groups involved (Brugha & Varvasovszky, 2000). The management of stakeholders and the 
implementation of the Action Plan run in a positive feedback loop, where better engagement of 
the stakeholders improves the implementation process, which in turn attracts more stakeholders 
important to program implementation. 
 
1. Federal Government 
The Minister of Health is responsible for protecting and promoting the health of Canadians, 
and this role is supported by the Health Portfolio (Health Canada, 2017). The Health 
Portfolio comprises Health Canada, the PHAC, the Canadian Institutes of Health Research, 
the Patented Medicine Prices Review Board, and the Canadian Food Inspection Agency. 
The PHAC is the federal lead in mobilizing pan-Canadian action to maintain and improve 
public health, and to prevent disease through building and sustaining a public health 
network in an open, transparent, and relevant fashion (Health Canada, 2017).  
 
2. Provincial Governments  
The Ontario Ministry of Health and Long-Term Care, Manitoba Health, the Saskatchewan 
Ministry of Health, the New Brunswick Department of Health, and the Institut National de 
Santé Publique du Québec are the provincial actors who have an important role in policy 
decisions regarding the prevention and control of Lyme disease in their respective provinces 
(PHAC, 2018c). These actors have set up visions, goals, objectives, and standards in order 
to play their respective roles using a collaborative public health response and coordinated 
care approach in their communities.  
 
3. Health Professionals 
The Canadian Medical Association is the professional association of Canadian physicians, 
uniting more than 85,000 members on health and medical matters. The Association’s rich 
history of advocacy for evidence-based practice led to some of Canada’s most important 
health policy modifications (Canadian Medical Association, n.d.). The Association of Medical 
Microbiology and Infectious Disease Canada (AMMI Canada) represents physicians, clinical 
microbiologists, and researchers from microbiology and infectious diseases fields. AMMI 
Canada aims to serve the public through education, research, and clinical practice (AMMI 
Canada, 2018). The College of Family Physicians of Canada regulates family physicians 
and establishes standards for their training, certification, and professional development (The 
College of Family Physicians of Canada, n.d.). Infection Prevention and Control Canada is a 
multidisciplinary association committed to the well-being and safety of Canadians by 
educating, standardizing, and advocating for infection control and prevention strategies 
(Infection Prevention and Control Canada, 2018). These health professional organizations 
operate at the national level and their representation in the engagement strategy will 
strengthen the Canada-wide policy perspective. 
 
4. Academia and Research 
Queen’s University, Mount Allison University, Bishop’s University, the G. Magnotta 
Foundation, and Lakehead University are some Canadian institutes located in Lyme 
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disease-affected provinces. These institutes are also involved in the engagement process in 
order to contribute the most current knowledge and evidence-based methods and practices. 
 
5. Patient Groups 
LymeHope, Voices of Canadians about Lyme (VOCAL), and the Canadian Lyme Disease 
Foundation (CanLyme) are some of the patient advocacy groups at the national level. 
Provincial Lyme disease associations include Manitoba Lyme Disease, Lyme Ontario, the 
Lyme Disease Association of Alberta, the Saskatchewan Lyme Disease Association, and 
the Nova Scotia Lyme Disease Support Group. These patient advocacy groups have been 
at the forefront of pushing the government’s response to Lyme disease in Canada (PHAC, 
2018c). They advocate for patients to be equal partners in Lyme disease policy 
development and push to standardize educational material for health care providers. 
 
WHAT CAN THEY BRING? 
Stakeholders bring various perspectives, expertise, and opinions. Valuing these viewpoints and 
integrating these competencies can produce the most coordinated and holistic response to 
Lyme disease (PHAC, 2018c). Researchers, for example, can contribute by providing the most 
up-to-date knowledge and scientific evidence. Health care professionals can provide valuable 
insight into effective clinical methods, highlight gaps in current best practices, and iterate 
challenges related to clinical diagnoses and treatment. Representatives from Indigenous 
populations can identify the impact of increasing incidence of Lyme disease on their cultural 
practices. At-risk and vulnerable populations require a more tailored approach for effective 
health protection and promotion awareness and activities. The employees of governmental 
organizations, such as Parks Canada, can highlight the hardships of maintaining health 
promotion and protection protocols in daily work-related activities. For example, employees may 
not be able to wear long-sleeved shirts and light-coloured clothing because of extreme heat or 
dress code requirements. Patients, families, and their caregivers can bring their personal and 
lived experiences in challenges of diagnosis, treatment, and recovery.  
 
ROUNDTABLE DISCUSSION 
Melissa thought about all the engagement activities undertaken so far to refine and guide the 
implementation of the Action Plan on Lyme Disease and updated the summary of recent 
activities in her QP note. She also included an update about the upcoming roundtable meeting 
with stakeholders as part of the engagement strategy. The roundtable discussion is one of the 
major coalition activities planned as part of the strategy, involving many of the stakeholders and 
partner groups. She has been preparing for this discussion with her manager and colleagues for 
the past six weeks. She understands that Lyme disease is not only an emerging public health 
concern, but that it is also a politically charged topic because of the ideological differences 
various stakeholders have regarding possible solutions for this problem. Patients’ perspectives 
on missed Lyme disease diagnosis and lack of universal guidelines for diagnosis and treatment 
make it a particularly sensitive topic for many groups. The political nature of Lyme disease and 
sensitivity attached to this topic make it a controversial subject. Disapproval of the term chronic 
Lyme disease in medical literature and the recommendation against long term antibiotic 
treatment add to the controversy (R. Ahmed, personal communication, 2018). Because of these 
factors, Melissa is skeptical about the end results of the roundtable discussion. 
 
The roundtable discussion will be an all-day event held in Ottawa. A large U-shaped table will 
be set up to let everyone listen to information and opinions firsthand and to foster new 
partnerships among participants. An external professional facilitator has been hired to facilitate 
the discussion and minimize bias in proposing concrete actionable items and identifying future 
roles and responsibilities. In the spirit of openness and transparency, the final list of attendees 
and their affiliations has been shared with all who will attend. The roundtable discussion will be 
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conducted in both official languages to ensure full participation from all attendees. Melissa and 
her team understand the importance of performing a detailed stakeholder analysis to facilitate 
the implementation of the Action Plan and discern the policy context. They have also prepared a 
logic model to appraise the feasibility of future directions of policy making. The team is aware of 
the theories of policy development and their implication on future modifications in forming Lyme 
disease policy. 
 
WHY ROUNDTABLE? 
The Federal Framework on Lyme Disease Act mandates the preparation and implementation of 
the Action Plan and the engagement of relevant stakeholders. The roundtable discussion is an 
important activity in the engagement strategy because it will not only bring a diverse group of 
partners together to have an open dialogue, but it will also help obtain a broad range of values 
and perspectives on the three pillars of the framework (Exhibit 2). A roundtable discussion is an 
excellent opportunity to explore answers to some crucial questions, including: What are the 
possible ways to expand data collection methods to include people who do not fit the classic 
case definition? What roles and responsibilities can be delegated to various stakeholders in 
order to advance collaborative work on Lyme disease? Which health care professionals should 
be targeted for best practices guidelines preparation? What should the public awareness 
campaign focus on? And what should the Lyme disease research network, which was recently 
granted $4 million to expand its research, prioritize? Although the long-term outcome of the 
engagement strategy is to protect Canadians from potential health risks associated with Lyme 
disease, the immediate outcome of the activities will determine the timeline and strategy for 
achieving this long-term outcome.  
 
The Health Professional Task Force at the PHAC invited potentially interested stakeholders to 
participate in the discussion. The team is hoping to have strong representation from all sectors 
at the national level to identify opportunities for collaboration and to continue to advance work 
on Lyme disease. Most of the organizations have accepted the invitations; others have decided 
to send a delegate to represent the organization; and a few have declined, stating that Lyme 
disease is not a priority task for them at the moment (Exhibit 3). It is critical to have a strong 
voice supporting the incorporation of evidence-based research into the unified federal response, 
and to be able to successfully achieve positive long-term outcomes for the Lyme disease 
strategy. 
 
CONTROVERSY 
Lyme disease is a politically charged topic. The Government of Canada emphasizes developing 
a national surveillance program, best practice guidelines, and standard educational materials to 
increase Canadians’ awareness about Lyme disease by exclusively using scientifically proven 
and evidence-informed methods and practices. Some of the Lyme disease advocacy groups 
have been at the forefront to push the federal response toward implementing a Lyme disease 
care model similar to the American model, which is based on partially validated methods of 
diagnosis and treatment. These patient groups advocate for patients to be considered equal 
partners in decision-making at the policy level. Although patients’ perspectives are critical to 
understanding the gaps related to diagnosis, treatment, and recovery, their experiences must be 
balanced with evidence-based information and expert opinion. There are many conflicts of 
ideology between patient advocacy groups and technical experts, which is why successful 
implementation of the roundtable discussion is critical for a smooth advancement of the Action 
Plan. 
 
Melissa finished her QP note and sent it to the Director so it could be approved and forwarded 
to the Minister’s office via the single window of the Infectious Disease Prevention and Control 
Branch. It was now 8:30 a.m. and she rolled out of bed and peeked inside her mother’s room. 
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Her mother has suffered from arthritis for the past nine years. She was initially labelled as a 
‘suspected case of Lyme’ but laboratory testing did not provide a formal diagnosis. Looking at 
the clock again, Melissa gets ready to go to the PHAC office at 130 Colonnade Road. On her 
drive, she thinks about her journey with Lyme disease so far and the uncertainties about the 
outcomes of the roundtable discussion.  
 
CONCLUSION 
Melissa has seen the Action Plan on Lyme Disease pass through evolutionary steps. As a very 
sensitive issue for a lot of people (for her also because of her mother’s condition), Lyme disease 
brings out many controversies and concerns among all stakeholders. Having an open dialogue 
to establish clear-cut responsibilities and expectations is the key to a successful implementation 
of the Action Plan. While going up the stairs, she thinks about the logistics and operations of the 
roundtable discussion and keeps asking the following questions: What will happen at the 
roundtable discussion? Who will represent the different organizations? Will the representatives 
be able to truly represent their organizational perspectives? Will they be able to stand by the 
evidence-based research approach? Will they be able to dissociate their personal experiences 
with Lyme disease diagnoses from their professional opinions? Will they be able to control their 
tone and tailor their messages according to the audience? Will this roundtable be able to 
advance the Action Plan further or push it back? Four years’ worth of her team’s time, energy, 
and efforts depend on the outcomes of this roundtable discussion. 
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EXHIBIT 1 
Five Locations Where Tick Bite and Lyme Disease Risks Are Known 
 
 
 
Source:  Public Health Agency of Canada, 2018a. 
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EXHIBIT 2 
 
 
 
 
 
Source: Created by Author, derived from Public Health Agency of Canada, 2018.  
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EXHIBIT 3 
 
List of Stakeholder Organizations (Accepted Invitation) 
 
Federal Government 
 Public Health Agency of Canada 
Provincial Government 
 New Brunswick Department of Health 
 Ontario Ministry of Health and Long-Term Care 
 Institut national de santé publique du Québec 
 Manitoba Health 
 Saskatchewan Ministry of Health 
Health Professionals 
 Indigenous Physicians Association of Canada 
 Association of Medical Microbiology and Infectious Disease Canada  
 Canadian Association of Naturopathic Doctors 
 Canadian Association of Schools of Nursing 
 Centre for Effective Practice 
 College of Family Physicians of Canada 
 Medical Prof. Corp. 
 Naturopathic Family Medicine Inc.  
 Society of Obstetricians and Gynecologists of Canada 
 Canadian Veterinary Medical Association 
Patient Groups 
 LymeHope 
 CanLyme 
 Voices of Canadians About Lyme (VOCAL) 
 Nova Scotia Lyme Disease Support Group 
 Manitoba Lyme Disease 
 LymeNB 
 Ontario Lyme Alliance 
 Lyme Ontario 
 Lyme Disease Association of Alberta 
 Saskatchewan Lyme Disease Association 
Academia/Research 
 Queen’s University 
 G. Magnotta Lyme Disease Research Lab (University of Guelph) 
 G. Magnotta Foundation  
 
List of Stakeholder Organizations (Regrets) 
 Canadian Medical Association 
 Ministère de la Santé et des Services sociaux 
 Association québécoise de la maladie de Lyme 
 Bishop’s University 
 Infection Prevention and Control Canada 
 Mount Allison University 
 Canadian Nurses Association 
 Canadian Paediatric Society 
 Lakehead University 
 
 
Source: Public Health Agency of Canada, 2018c.  
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BACKGROUND 
Melissa Doug is a senior policy analyst at the Centre for Food-Borne, Environmental and 
Zoonotic Infectious Diseases at the Public Health Agency of Canada. She has been tasked with 
preparing Question Period (QP) notes for the Minister of Health. She has very little time to 
prepare a clear, succinct, and jargon-free note by 8:30 a.m. for the Director’s approval. Once 
the note is approved, the Director will forward it to the Minster of Health with an update on the 
status of activities being undertaken for the Action Plan on Lyme Disease. The QP note also 
includes an update on the upcoming roundtable discussion with stakeholders as part of the 
Lyme disease engagement strategy. Melissa has been working on Lyme disease policy for 
more than four years and her team’s energy and efforts will come to fruition during this 
roundtable discussion.  
 
Lyme disease is a rapidly growing public health challenge in Canada. The absence of a 
consolidated national response to Lyme disease led to the Federal Framework on Lyme 
Disease Act, which mandated the Minister of Health to call a national conference on the issue. 
The Public Health Agency of Canada developed the federal Action Plan on Lyme Disease on 
behalf of the Minister of Health. The Action Plan is based on three pillars—surveillance, 
education and awareness, and guidelines and best practices. Developing the plan requires 
comprehensive consultation with all stakeholder groups to ensure that diverse perspectives in 
policy development and implementation are incorporated. Stakeholder engagement in the 
implementation process is key to addressing the specific needs of at-risk groups and narrowing 
the gaps in current practices at the policy level.  
 
The purpose of this case is to underscore the importance of stakeholder analysis and 
management in defining future policy directions and successful program implementation. 
Incorporating the real-world perspectives of diverse stakeholders is an essential component of 
an effective policy-making process. 
 
OBJECTIVES 
1. Develop strategies for stakeholder identification to inform population-based policies. 
2. Analyze the significance of various stakeholder analysis techniques in order to address 
emerging public health issues.  
3. Construct a map of relevant stakeholders on an interest–influence matrix for a structured 
approach to stakeholder analysis. 
4. Practice compiling evidence to synthesize policy brief communication with imperfect and 
incomplete information regarding emerging infectious diseases. 
5. Appraise the value of building partnerships to advocate for evidence-informed policies. 
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DISCUSSION QUESTIONS 
1. What is the role of evidence-based research in policy development? 
2. What are the facilitators and barriers of stakeholder engagement activities? 
3. How does stakeholder engagement facilitate the implementation of an action plan? 
4. What are the various characteristics of the stakeholders interested in Lyme disease 
engagement strategy? 
5. Can international guidelines regarding emerging vector-borne infections be used to inform 
best practice guidelines in Canada? 
6. How does the federal government perspective on Lyme disease differ from that of 
nonfederal and other external organizational perspectives? How does it impact stakeholder 
engagement? 
 
KEYWORDS 
Communication; federal framework; Lyme disease; policy development; stakeholder analysis 
